BBA
CYT

Baker Bros. Advisors’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Baker Bros. Advisors’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,492,118
Closed -$4.11M – 115
2022
Q4 		$4.11M Sell
2,492,118
-151,522
-6% -$243K 0.02% 83
2022
Q3 		$5.08M Hold
2,643,640
– – 0.03% 79
2022
Q2 		$7.9M Buy
2,643,640
+1,831,000
+225% +$4.68M 0.04% 69
2022
Q1 		$3.06M Hold
812,640
– – 0.02% 97
2021
Q4 		$9.24M Hold
812,640
– – 0.05% 79
2021
Q3 		$14.3M Hold
812,640
– – 0.06% 69
2021
Q2 		$17.4M Buy
+812,640
New +$15.2M 0.08% 64

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $133M AUM 42.18% 1-Year Est. Return

Baker Bros. Advisors's CYT Position: Q1 2023 in Review

Baker Bros. Advisors sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2023, closing a stake of 2,492,118 shares — an estimated $4.11M sold.

Baker Bros. Advisors first reported a position in CYT in Q2 2021 and held it in 7 quarters. The position peaked at $17.4M in Q2 2021. 32 funds tracked by Wall St. Rank hold CYT as of Q1 2023.

  • Baker Bros. Advisors reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,492,118 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4.11M.
  • Baker Bros. Advisors first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
  • Baker Bros. Advisors's Cyteir Therapeutics, Inc. Common Stock position peaked at $17.4M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.